Patel Samir Rashmikant — SEC Form 4 filings
SEC reporting owner CIK 1702447. 15 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-06-04 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | Director, 10% owner | 15 | — | — | 31 |
Form 4 filings — Patel Samir Rashmikant
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | Akari Therapeutics Plc (AKTX) | Option exercise (M): 1,209 @ $8 · Option exercise (M): 15,466 @ $0.00 · Option exercise (M): 5,799 @ $0.00 · Option exercise (M): 1,209 (derivative) @ $32 · Option exercise (M): 15,466 (derivative) @ $16.16 · Option exercise (M): 5,799 (derivative) @ $16.16 | EDGAR |
| 2025-12-18 | 4 | Akari Therapeutics Plc (AKTX) | Purchase (P): 618,658 (derivative) · Purchase (P): 618,658 (derivative) @ $0.40 · Purchase (P): 231,997 (derivative) · Purchase (P): 231,997 (derivative) @ $0.40 | EDGAR |
| 2025-03-24 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 406,250 @ $1.12 · Grant/award (A): 406,250 (derivative) @ $1.12 · Grant/award (A): 406,250 (derivative) @ $1.12 | EDGAR |
| 2025-01-07 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 208,000 @ $0.00 · Grant/award (A): 152,672,000 (derivative) @ $0 | EDGAR |
| 2024-12-30 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 3,200,000 @ $0.00 · Grant/award (A): 400,000 @ $0.00 | EDGAR |
| 2024-12-27 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 7,500,000 @ $0.00 | EDGAR |
| 2024-12-26 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 1,400,000 @ $0.00 | EDGAR |
| 2024-12-26 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 1,400,000 @ $0.00 | EDGAR |
| 2024-12-03 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 419,286,000 @ $0.00 · Grant/award (A): 162,604,000 (derivative) @ $0 · Grant/award (A): 419,286,000 (derivative) @ $0.00 | EDGAR |
| 2024-11-18 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 1,404,622,000 | EDGAR |
| 2024-11-01 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 79,684,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 175,080,000 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 91,396,000 @ $0 | EDGAR |
| 2024-06-04 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 1,326,258,000 @ $0.00 · Grant/award (A): 1,326,258,000 (derivative) @ $0.00 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1702447 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →